Compare Danaher Corporation (DHR) vs Symbotic Inc (SYM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Danaher Corporation vs Symbotic Inc — how do they compare? Danaher Corporation trades at $207.45 (market cap $145.83B), while Symbotic Inc trades at $41.14 (market cap $5.41B). The key difference: Danaher Corporation is far larger — about 27× Symbotic Inc's market cap, and Danaher Corporation pays a 0.77% dividend while Symbotic Inc pays none. Which is the better fit depends on your goals.
| DHR | SYM | |
|---|---|---|
Market Cap | $145.83B | $5.41B |
Sector | Health | Technology |
52-Week High | $242.05 | $87.30 |
52-Week Low | $161.91 | $38.57 |
Enterprise Value | $168.04B | $3.67B |
Dividend Yield | 0.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Danaher (DHR) trades at $209.26, up 2.2% today, with strong technical momentum as the price sits above key support levels. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 EPS expected at $1.92. Fundamentals show robust profitability with a 58.51% gross margin and 15.95% net income margin, though revenue growth has been modest. Analyst sentiment is overwhelmingly positive with 69% buy ratings and a $202.33 consensus price target. Recent news highlights the acquisition of Masimo and new product launches in its biotechnology segment.
The outlook for DHR remains favorable driven by earnings beats and strategic acquisitions, but investors face risks from elevated valuation multiples and potential macroeconomic headwinds. The stock's current technical overbought condition suggests near-term consolidation may occur, yet long-term growth prospects in life sciences support a bullish stance. Key watch points include Q3 2026 earnings results and integration progress of recent acquisitions.
SYM trades at $41.15, up 2.59% with recent earnings misses creating volatility. The stock shows bearish technical signals despite analyst optimism, with revenue growth of 21.7% in Q3 2026 but declining profitability margins. Recent institutional selling and insider transactions add complexity to the investment case.
Outlook remains mixed with strong revenue growth potential offset by margin pressures and recent earnings disappointments. The consensus price target of $60 suggests 46% upside, but investors face execution risks and competitive threats in the automation sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →About Symbotic Inc
Symbotic is an automation technology leader that provides an end-to-end, A.I.-powered robotic platform for large-scale warehouse operations. By utilizing untethered, high-speed autonomous bots and sophisticated vision systems, Symbotic transforms traditional distribution centers into high-density strategic assets. The company serves the world’s largest retailers and wholesalers—most notably Walmart—while expanding into 'Warehouse-as-a-Service' through its GreenBox joint venture to democratize advanced automation for smaller enterprises.
Read more on SYM →
